Daiichi Sankyo (OTCMKTS:DSNKY) Stock Rating Lowered by Zacks Research

Daiichi Sankyo (OTCMKTS:DSNKY) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Tuesday, Zacks reports.

Separately, Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce”.

Daiichi Sankyo Trading Down 0.1%

Shares of DSNKY stock opened at $17.90 on Tuesday. Daiichi Sankyo has a 12-month low of $14.98 and a 12-month high of $27.50. The company has a market capitalization of $33.35 billion, a PE ratio of 20.81, a price-to-earnings-growth ratio of 1.91 and a beta of -0.11. The firm has a 50 day moving average price of $17.79 and a two-hundred day moving average price of $17.16. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, analysts predict that Daiichi Sankyo will post 0.93 earnings per share for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.